UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.
For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.
Hematologic Malignancies (IRB-HSR #20613)
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
Primary Investigator: Laahn Foster
Clinical Research Coordinators: Michal Ande
Hematologic Malignancies (IRB-HSR #20729)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Primary Investigator: Craig Portell
Clinical Research Coordinator: Amelia Hodson, Kristen L. Johnson
Hematologic Malignancies
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
Primary Investigator: Karen Ballen
Clinical Research Coordinator: Amelia Hodson
Thoracic Oncology (IRB-HSR #20704)
A Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced squamous or non-squamous NSCLC and previous clinical benefit on treatment with a PD-1 or PD-L1 inhibitor (NCT03041181)
Primary Investigator: Richard Hall
Clinical Research Coordinator: Gracie Tubbs Hockenberry
Idiopathic Parkinson’s Disease (IRB-HSR #180001)
A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System (NCT03319485)
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Idiopathic Parkinson’s Disease (IRB-HSR #17552)
A Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Chronic Trigeminal Neuropathic Pain (IRB-HSR #170004)
A Feasibility Study of Focused Ultrasound to Perform Bilateral Medial Thalamotomy for the Treatment of Chronic Trigeminal Neuropathic Pain (NCT03309813)
Primary Investigator: W. Jeffrey Elias
Clinical Research Coordinator: Matthew Patterson
Newly Diagnosed Glioblastoma (IRB-HSR #19800)
INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT). (NCT02977780)
Primary Investigator: David Schiff
Clinical Research Coordinator: Starlene Truslow
Newly Diagnosed Glioblastoma (IRB-HSR #20105)
A Phase I Study Targeting Newly Diagnosed Glioblastoma with anti-CD3 x anti-EGFR Bispecific Antibody Armed T cells (EGFR BATs) in Combination with Radiation and Temozolomide (NCT03344250)
Primary Investigator: Camilo Fadul
Clinical Research Coordinator: Melissa Otoya
Newly Diagnosed & Recurrent Glioblastoma (IRB-HSR #170002)
A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma (NCT03150862)
Primary Investigator: David Schiff
Clinical Research Coordinator: Carol Woodburn
Recurrent Glioblastoma or Anaplastic Astrocytoma (IRB-HSR #18471)
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma (NCT02414165)
Primary Investigator: David Schiff
Clinical Research Coordinator: Starlene Truslow
Recurrent IDH1-R132X Mutant Advanced Solid Tumors (IRB-HSR #170009)
An Open-Label, Non-Randomized, Multi-center Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY 1436032 and to Characterize its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-Tumor Activity in Patients with IDH1-R132X Mutant Advanced Solid Tumors. (NCT02746081)
Primary Investigator: David Schiff
Clinical Research Coordinator: Carol Woodburn
